![Mark Wilkinson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark A. Wilkinson is the founder of Impact Technology Development.
Prior to founding Impact Technology Development, he worked as a Director at Pelias Therapeutics, a Principal at Cabot Corp., a Principal at Molten Metal Technology, Inc., and as an Executive Vice President at Voltaix LLC from 2004 to 2012.
Wilkinson received his undergraduate and doctorate degrees from McGill University and a doctorate degree from Massachusetts Institute of Technology.
| Unternehmen | Position | Beginn |
|---|---|---|
Impact Technology Development
 Impact Technology Development Miscellaneous Commercial ServicesCommercial Services Impact Technology Development is a contract technology development and consulting firm specializing in chemical engineering, chemistry research, process and product development, and industrial process engineering. The private company is based in Lincoln, MA. The company serves clients across industries such as pharmaceuticals, biopharmaceuticals, specialty chemicals, metallurgical processes, medical devices, diagnostics, and alternative energy, offering services that include chemistry optimization, process engineering, and front-end engineering design packages for commercial facility construction. Impact Technology Development provides laboratory and pilot-scale facilities for development, testing, and scale-up, and operates a flexible contract development model that gives clients access to technical staff and shared infrastructure. The company also assists with intellectual property portfolio development, technology transfer, quality improvement initiatives, and third-party technology assessments and due diligence services for investors. The company was founded by Mark A. Wilkinson. Mark A. Wilkinson has been the CEO since incorporation. | Vorstandsvorsitzender | - |
| Unternehmen | Position | Ende |
|---|---|---|
Pelias Therapeutics | Direktor/Vorstandsmitglied | - |
| CABOT CORPORATION | Corporate Officer/Principal | - |
Molten Metal Technology, Inc.
 Molten Metal Technology, Inc. Environmental ServicesIndustrial Services Engages in innovative and proprietary | Corporate Officer/Principal | - |
Voltaix LLC
 Voltaix LLC Chemicals: Major DiversifiedProcess Industries Manufactures specialty chemicals | Geschäftsführer | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 7 |
|---|---|
Cabot Corp.
 Cabot Corp. Chemicals: SpecialtyProcess Industries Manufactures and supplies carbon black and performance chemicals | Process Industries |
Molten Metal Technology, Inc.
Molten Metal Technology, Inc. Environmental ServicesIndustrial Services Engages in innovative and proprietary | Industrial Services |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Voltaix LLC
Voltaix LLC Chemicals: Major DiversifiedProcess Industries Manufactures specialty chemicals | Process Industries |
Impact Technology Development
Impact Technology Development Miscellaneous Commercial ServicesCommercial Services Impact Technology Development is a contract technology development and consulting firm specializing in chemical engineering, chemistry research, process and product development, and industrial process engineering. The private company is based in Lincoln, MA. The company serves clients across industries such as pharmaceuticals, biopharmaceuticals, specialty chemicals, metallurgical processes, medical devices, diagnostics, and alternative energy, offering services that include chemistry optimization, process engineering, and front-end engineering design packages for commercial facility construction. Impact Technology Development provides laboratory and pilot-scale facilities for development, testing, and scale-up, and operates a flexible contract development model that gives clients access to technical staff and shared infrastructure. The company also assists with intellectual property portfolio development, technology transfer, quality improvement initiatives, and third-party technology assessments and due diligence services for investors. The company was founded by Mark A. Wilkinson. Mark A. Wilkinson has been the CEO since incorporation. | Commercial Services |
Pelias Therapeutics |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
